Dasatinib

规格

302962-49-8CAS 号

801-607-0EC 号

N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamideIUPAC 名称

C22H26ClN7O2S化学式

488 g/mol分子量

Dasatinib; 302962-49-8; Sprycel; BMS-354825; Dasatinib anhydrous; BMS354825; Dasatinib (anhydrous); BMS 354825; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; dasatinibum; anh. dasatinib; N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE; anhydrous dasatinib; dasatinib (anh.); N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; DTXSID4040979; BMS Dasatinib; X78UG0A0RN; NSC732517; 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-; DTXCID2020979; CHEBI:49375; 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-; NSC-759877; n-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide; JLTN compound; PHYRAGO; 354825, BMS; RefChem:5732; L01XE06; 801-607-0; 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate; BMS-354825 HYDRATE; BMS-354825-03; N-(2-Chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide hydrate; RBZ1571X5H; Dasatinib (BMS-354825); C22H26ClN7O2S; N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide; MFCD11046566; CHEMBL1421; s1021; NSC-732517; NCGC00181129-01; N-(2-chloro-6-methyl-phenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methyl-pyrimidin-4-yl]amino]thiazole-5-carboxamide; SMR002529551; CAS-302962-49-8; Dasatinib [USAN:INN]; UNII-X78UG0A0RN; Dasatanib; 1N1; Dasatinib (Standard); Kinome_3650; Dasatinib (JAN/INN); DASATINIB [INN]; DASATINIB [MI]; Sprycel (Bristol Meyers); DASATINIB [WHO-DD]; SCHEMBL8226; Dasatinib,BMS-354825; MLS003915609; MLS004774145; MLS006010904; Dasatinib - Bio-X trade mark; GTPL5678; orb1308592; orb3141253; SCHEMBL3301361; SCHEMBL29381185; BDBM13216; cid_3062316; Dasatinib (BMS-354825)?; EX-A401; 5-Thiazolecarboxamide, monohydrate; GLXC-90166; HMS2043N05; HMS3244A05; HMS3244A06; HMS3244B05; HMS3265C19; HMS3265C20; HMS3265D19; HMS3265D20; HMS3654K05; HMS3744C11; HMS5079O03; Pharmakon1600-01502275; Tox21_112736; EBC-11324; HY-10181R; NSC759877; NSC800087; AKOS015902363; Tox21_112736_1; BMS 345825; CCG-264779; CS-0100; DB01254; FC36515; GS-6548; NSC-800087; SB17284; SDCCGSBI-0061713.P004; NCGC00181129-02; NCGC00181129-03; NCGC00181129-05; NCGC00181129-06; NCGC00181129-07; NCGC00181129-12; NCGC00181129-14; NCGC00181129-21; NCGC00181129-22; NCGC00481571-01; 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide; AC-22749; BCB03_000715; BD300052; BMS 35482513; HY-10181; Sprycel BMS-354825 Dasatinib anhydrous; D5949; NS00001968; PA-3062316; SW208076-5; D-3307; D03658; EN300-123025; AB01273956-01; AB01273956-02; AB01273956_03; AR-270/43507994; D023721; F050286; Q419940; SR-00000000554; SR-00000000554-5; BRD-K49328571-001-05-1; BRD-K49328571-001-07-7; BRD-K49328571-001-15-0; BRD-K49328571-001-19-2; Z1546610486; 2-{6-[4-(2-Hydroxy-ethyl)-piperazin-1-yl]-2-methyl-pyrimidin-4-ylamino}-thiazole; N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl}amino)-1,3-thiazole-5-carboxamide; N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide同义词